MC
Therapeutic Areas
Olema Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Palazestrant (OP-1250) | ER+/HER2- Metastatic Breast Cancer (2nd/3rd line monotherapy) | Phase 3 |
| OP-3136 | Breast Cancer and Other Solid Tumors | Phase 1 |
Leadership Team at Olema Pharmaceuticals
SP
Sean P. Bohen, M.D., Ph.D.
President and CEO
SM
Shawnte M. Mitchell, J.D.
Chief Legal Officer and Corporate Secretary
DC
David C. Myles, Ph.D.
Chief Scientific Officer
NZ
Naseem Zojwalla, M.D.
Chief Medical Officer
JD
Julie Dexter
Senior Vice President and Head of People
AD
Angelos Dovletoglou, Ph.D.
Senior Vice President, CMC and Supply Chain
RH
Richard Hernandez
Senior Vice President, Clinical Development Operations
KK
Kamesh Kuchimanchi, Ph.D.
Senior Vice President, Regulatory Affairs and Quality Assurance
MS
Mark Shilkrut, M.D., Ph.D.
Senior Vice President, Clinical Development
IC
Ian Clark
Chairman of the Board